Trials / Completed
CompletedNCT01850966
Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid Arthritis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,747 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To investigate the safety and efficacy of the administration of Iguratimod (CRM01T) for 52 weeks in patients with rheumatoid arthritis in clinical practice
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iguratimod | The usual adult dosage for oral use of 25 mg tablet of iguratimod once daily for 4 weeks or more, after which the dosage should be increased to one 25 mg tablet taken twice daily. |
Timeline
- Start date
- 2012-09-12
- Primary completion
- 2014-04-13
- Completion
- 2014-04-13
- First posted
- 2013-05-10
- Last updated
- 2018-11-05
Locations
453 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01850966. Inclusion in this directory is not an endorsement.